New #AMD study links higher systemic alternative complement activation with faster geographic atrophy growth, highlighting potential blood biomarkers. #GeographicAtrophy #Retina buff.ly/mszS13x
Latent Correlations Between Longitudinal Systemic Complement Factors and Geographic Atrophy Growth Rate - PubMed
Systemic alternative pathway biomarkers demonstrated the strongest positive associations with GA growth rate. The pattern of associations in this exploratory analysis supports a hypothesis-generating…
buff.ly
November 2, 2026 at 10:01 AM
New #AMD study links higher systemic alternative complement activation with faster geographic atrophy growth, highlighting potential blood biomarkers. #GeographicAtrophy #Retina buff.ly/mszS13x
New #AMD research: C3 inhibition protects RPE cells beyond what C5 blockade achieves, highlighting non-lytic complement damage in retinal degeneration. #GeographicAtrophy #Retina buff.ly/47crL01
A Mechanistic Dissection of Multifaceted Complement Attack in Age-Related Macular Degeneration Reveals the Superiority of C3 Inhibition - PubMed
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in the elderly, and geographic atrophy (GA) represents its advanced atrophic form. While C5 and C3…
buff.ly
October 30, 2026 at 10:00 AM
New #AMD research: C3 inhibition protects RPE cells beyond what C5 blockade achieves, highlighting non-lytic complement damage in retinal degeneration. #GeographicAtrophy #Retina buff.ly/47crL01
In a US study of 77 patients with geographic atrophy, preserving reading drove treatment choices and 86% preferred a one-time injection. buff.ly/m5SVyc7
#AMD #Retina #GeographicAtrophy
#AMD #Retina #GeographicAtrophy
US Patients’ Preferences for Geographic Atrophy Treatment | OPTH | Dove Medical Press
2 complement inhibitors used for treating geographic atrophy secondary to age-related macular degeneration and other treatments are being developed
buff.ly
October 14, 2026 at 9:01 AM
In a US study of 77 patients with geographic atrophy, preserving reading drove treatment choices and 86% preferred a one-time injection. buff.ly/m5SVyc7
#AMD #Retina #GeographicAtrophy
#AMD #Retina #GeographicAtrophy
Science Corp's PRIMA Implant Restores Reading Ability in First Stargardt Patient
..................
https://nile1.com/science-corps-prima-implant-restores-reading-ability-in-first-stargardt-patient/
..................
#brain-computerInterface #geographicAtrophy #maxHodak #photovoltaicRetinalImplant
..................
https://nile1.com/science-corps-prima-implant-restores-reading-ability-in-first-stargardt-patient/
..................
#brain-computerInterface #geographicAtrophy #maxHodak #photovoltaicRetinalImplant
October 13, 2026 at 11:26 PM
Science Corp's PRIMA Implant Restores Reading Ability in First Stargardt Patient
..................
https://nile1.com/science-corps-prima-implant-restores-reading-ability-in-first-stargardt-patient/
..................
#brain-computerInterface #geographicAtrophy #maxHodak #photovoltaicRetinalImplant
..................
https://nile1.com/science-corps-prima-implant-restores-reading-ability-in-first-stargardt-patient/
..................
#brain-computerInterface #geographicAtrophy #maxHodak #photovoltaicRetinalImplant
Patients with #GeographicAtrophy (GA) following age-related macular degeneration may benefit from pegcetacoplan long-term, according to research presented at the American Academy of Optometry 2026 annual meeting. @aaopt.bsky.social
Learn more: https://bit.ly/4AIlXsY
Learn more: https://bit.ly/4AIlXsY
Early Pegcetacoplan Therapy Leads to Better Retinal Tissue Preservation At Year 5
Extended treatment with pegcetacoplan reduces geographic atrophy progression and preserves retinal tissue over 5 years.
bit.ly
October 2, 2026 at 8:12 PM
Patients with #GeographicAtrophy (GA) following age-related macular degeneration may benefit from pegcetacoplan long-term, according to research presented at the American Academy of Optometry 2026 annual meeting. @aaopt.bsky.social
Learn more: https://bit.ly/4AIlXsY
Learn more: https://bit.ly/4AIlXsY
Continuous pegcetacoplan treatment for up to 48 months can progressively slow #GeographicAtrophy growth and preserve retinal tissue, according to results of a study published in the American Journal of Ophthalmology.
Learn more: https://bit.ly/4dmiciN
Ophthalmology #Retina #MedTwitter
Learn more: https://bit.ly/4dmiciN
Ophthalmology #Retina #MedTwitter
Earlier Pegcetacoplan Better Preserves Retinal Tissue in Geographic Atrophy
Early and continuous pegcetacoplan therapy slows geographic atrophy progression and preserves retinal tissue in AMD.
bit.ly
September 17, 2026 at 12:06 AM
Continuous pegcetacoplan treatment for up to 48 months can progressively slow #GeographicAtrophy growth and preserve retinal tissue, according to results of a study published in the American Journal of Ophthalmology.
Learn more: https://bit.ly/4dmiciN
Ophthalmology #Retina #MedTwitter
Learn more: https://bit.ly/4dmiciN
Ophthalmology #Retina #MedTwitter
More like she's blind as a bat. #AgeRelatedMacularDegeneration #GeographicAtrophy I have something to "look" forward to. Actually, I hope not.
June 28, 2026 at 5:36 PM
More like she's blind as a bat. #AgeRelatedMacularDegeneration #GeographicAtrophy I have something to "look" forward to. Actually, I hope not.
#PortfolioNews | #SparingVision receives #FDA support to launch Phase II trial of SPVN06 in #GeographicAtrophy
🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss
👉 buff.ly/m0BlGti
#GeneTherapy
🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss
👉 buff.ly/m0BlGti
#GeneTherapy
April 22, 2025 at 2:44 PM
#PortfolioNews | #SparingVision receives #FDA support to launch Phase II trial of SPVN06 in #GeographicAtrophy
🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss
👉 buff.ly/m0BlGti
#GeneTherapy
🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss
👉 buff.ly/m0BlGti
#GeneTherapy
Another huge step forward in the story of CTx001. And another outstanding milestone achieved by the team at CTx. Congratulations, everyone!
It's come a long way from sitting on a piece of paper somewhere in @fbmh-uom.bsky.social @prof-clark.bsky.social
www.linkedin.com/posts/geneth...
It's come a long way from sitting on a piece of paper somewhere in @fbmh-uom.bsky.social @prof-clark.bsky.social
www.linkedin.com/posts/geneth...
#genetherapy #ophthalmology #clinicaltrials #biotech #geographicatrophy #amd #ctx001 | Complement Therapeutics
📢 First patient dosed in Opti-GAIN interventional study
Complement Therapeutics has dosed the first patient in Opti-GAIN, our first-in-human Phase I/II trial of CTx001 in Geographic Atrophy (GA) seco...
www.linkedin.com
March 25, 2026 at 9:33 AM
Another huge step forward in the story of CTx001. And another outstanding milestone achieved by the team at CTx. Congratulations, everyone!
It's come a long way from sitting on a piece of paper somewhere in @fbmh-uom.bsky.social @prof-clark.bsky.social
www.linkedin.com/posts/geneth...
It's come a long way from sitting on a piece of paper somewhere in @fbmh-uom.bsky.social @prof-clark.bsky.social
www.linkedin.com/posts/geneth...
#ASRS2026: Real-world evidence shows pegcetacoplan treatment, alone or with anti-VEGF therapy, may help prevent rapid visual acuity loss in #GeographicAtrophy (GA), maintaining stable vision through 12 months.
Learn more: https://bit.ly/3TLhQLy
Learn more: https://bit.ly/3TLhQLy
Pegcetacoplan Keeps Visual Acuity Loss to a Minimum, Real World Research Shows - Ophthalmology Advisor
A real-world analysis assessed visual acuity outcomes among patients with geographic atrophy receiving pegcetacoplan.
bit.ly
July 20, 2026 at 5:37 PM
#ASRS2026: Real-world evidence shows pegcetacoplan treatment, alone or with anti-VEGF therapy, may help prevent rapid visual acuity loss in #GeographicAtrophy (GA), maintaining stable vision through 12 months.
Learn more: https://bit.ly/3TLhQLy
Learn more: https://bit.ly/3TLhQLy
#Ophthalmology #clinicaltrial #dryAMDtreatment #PST611 #PulseSightTherapeutics #phase1safetystudy #genetherapy #geographicatrophy #GA #nonviralgenetherapy #dryagerelatedmaculardegeneration #AMD #DryAMD #PST611CT1study #electrotransfectiontechnology #DNAplasmids
pharmatimes.com/news/first-p...
pharmatimes.com/news/first-p...
First patient dosed in trial for novel dry AMD treatment PST-611 - PharmaTimes
PulseSight begins phase 1 safety study of gene therapy for geographic atrophy
pharmatimes.com
July 10, 2025 at 10:17 AM
A midstage trial of #Ocugen's #genetherapy for sight-robbing disease #geographicatrophy (GA) showed efficacy – but still sparked a selloff in its #stock.
pharmaphorum.com/news/ocugen-...
pharmaphorum.com/news/ocugen-...
Ocugen shares fall, despite positive eye disorder trial
A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.
pharmaphorum.com
January 16, 2026 at 1:16 PM
A midstage trial of #Ocugen's #genetherapy for sight-robbing disease #geographicatrophy (GA) showed efficacy – but still sparked a selloff in its #stock.
pharmaphorum.com/news/ocugen-...
pharmaphorum.com/news/ocugen-...
#Sanofi has been granted a speedy review from the #FDA for a gene therapy for #geographicatrophy (GA), a complication of #agerelatedmaculardegeneration (AMD), as it prepares to test it in a clinical trial.
pharmaphorum.com/news/fda-fas...
pharmaphorum.com/news/fda-fas...
July 16, 2025 at 5:37 PM
#Sanofi has been granted a speedy review from the #FDA for a gene therapy for #geographicatrophy (GA), a complication of #agerelatedmaculardegeneration (AMD), as it prepares to test it in a clinical trial.
pharmaphorum.com/news/fda-fas...
pharmaphorum.com/news/fda-fas...
Proud to have contributed to the @ema.europa.eu workshop on Geographic Atrophy endpoints. From the opening patient perspective by Avril Daly to expert panels with RI contributors, patient voice was part of the conversation throughout. More to come from the EMA. #GeographicAtrophy #PatientVoice
![[ID: Screenshot of the title slide from Avril Daly’s presentation, displayed on a blue and white background and reads: “European Medicines Regulatory Network (EMRN) workshop on Geographic Atrophy endpoints – Patients Perspective.” Underneath that is the presenter’s information - Avril Daly, CEO of Retina International. The Retina International logo is in the bottom right corner. Along the top of the screen, smaller video thumbnails show other workshop participants.]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:lv77yzq75a4ryjpz6bu2nc5d/bafkreiex2ybgnuealqrtrtp2zqpmmlwb2omvwdm2vtahtz2d244ctf7gcu)
![[ID: Screenshot of Nabin Paudel from Retina International speaking as part of a panel discussion on visual functional endpoints for Geographic Atrophy. The Retina International logo is in the top right corner.]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:lv77yzq75a4ryjpz6bu2nc5d/bafkreiet2sidx5j76tl34m7eqaino3lty7ejstzvyczjfj3pbgnbesqwja)
![[ID: Screenshot from Avril Daly’s presentation with Retina International’s three core pillars: Empower, Advocate, and Innovate, shown in a circular diagram. “Empower” appears in blue, “Advocate” in orange, and “Innovate” in yellow, with the Retina International logo at the centre.]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:lv77yzq75a4ryjpz6bu2nc5d/bafkreids4xull4he5e6u4ur4ds447xmezqswja2j23fuv5hzerhvhnmin4)
May 1, 2026 at 10:01 AM
Proud to have contributed to the @ema.europa.eu workshop on Geographic Atrophy endpoints. From the opening patient perspective by Avril Daly to expert panels with RI contributors, patient voice was part of the conversation throughout. More to come from the EMA. #GeographicAtrophy #PatientVoice
Our @arvoinfo.bsky.social #SIG on GA trial endpoints is today. Join global experts + patient voices to rethink what meaningful outcomes look like.
Last chance to register! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social #GeographicAtrophy #ClinicalTrials
Last chance to register! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social #GeographicAtrophy #ClinicalTrials
June 10, 2025 at 9:40 AM
Our @arvoinfo.bsky.social #SIG on GA trial endpoints is today. Join global experts + patient voices to rethink what meaningful outcomes look like.
Last chance to register! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social #GeographicAtrophy #ClinicalTrials
Last chance to register! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social #GeographicAtrophy #ClinicalTrials
Our @arvoinfo.bsky.social #SIG on #GeographicAtrophy endpoints is just 2 weeks away. Join us on June 10 to help shape more meaningful trial outcomes.
🔗 Register today! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social @ema.europa.eu #GeographicAtrophy #ClinicalTrials
🔗 Register today! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social @ema.europa.eu #GeographicAtrophy #ClinicalTrials
May 29, 2025 at 10:53 AM
Our @arvoinfo.bsky.social #SIG on #GeographicAtrophy endpoints is just 2 weeks away. Join us on June 10 to help shape more meaningful trial outcomes.
🔗 Register today! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social @ema.europa.eu #GeographicAtrophy #ClinicalTrials
🔗 Register today! www.arvo.org/education/sp...
@avrilbdaly.bsky.social @nabinpaudel.bsky.social @ema.europa.eu #GeographicAtrophy #ClinicalTrials
How do we make GA clinical trials more patient-focused?
Join our virtual @arvoinfo.bsky.social SIG session:
June 10, 9-10:30am EDT.
Hosted by @retinaint.bsky.social - open discussion encouraged!
🔗 Register: www.arvo.org/education/sp...
#GeographicAtrophy #RetinaResearch #ClinicalTrials #AMD
Join our virtual @arvoinfo.bsky.social SIG session:
June 10, 9-10:30am EDT.
Hosted by @retinaint.bsky.social - open discussion encouraged!
🔗 Register: www.arvo.org/education/sp...
#GeographicAtrophy #RetinaResearch #ClinicalTrials #AMD
May 21, 2025 at 9:59 AM
How do we make GA clinical trials more patient-focused?
Join our virtual @arvoinfo.bsky.social SIG session:
June 10, 9-10:30am EDT.
Hosted by @retinaint.bsky.social - open discussion encouraged!
🔗 Register: www.arvo.org/education/sp...
#GeographicAtrophy #RetinaResearch #ClinicalTrials #AMD
Join our virtual @arvoinfo.bsky.social SIG session:
June 10, 9-10:30am EDT.
Hosted by @retinaint.bsky.social - open discussion encouraged!
🔗 Register: www.arvo.org/education/sp...
#GeographicAtrophy #RetinaResearch #ClinicalTrials #AMD
New insights into #GeographicAtrophy care: a study reveals how US retina specialists balance efficacy, safety & treatment burden in evolving #AMD management. #Retina #Ophthalmology #MedResearch buff.ly/8HCwo1G
US Retina Specialists' Preferences for Geographic Atrophy Treatment - PubMed
Across patient profiles, RS prioritized lesion growth rate reduction over risks; intravitreal injection frequency was the least important. However, RS were more risk-tolerant with patients with…
buff.ly
June 23, 2026 at 9:01 AM
New insights into #GeographicAtrophy care: a study reveals how US retina specialists balance efficacy, safety & treatment burden in evolving #AMD management. #Retina #Ophthalmology #MedResearch buff.ly/8HCwo1G
Novel insight in #AMD research: a new spatially weighted model captures the true impact of #GeographicAtrophy beyond lesion size. A step toward smarter #Retina imaging. #Ophthalmology #MedTech #VisionScience buff.ly/pes2x9B
Development of a conceptual, HOV-inspired spatial weighting model for quantifying geographic atrophy severity - PubMed
The HOV-inspired severity score provides a spatially weighted framework for assessing GA progression and may complement conventional structural metrics by incorporating lesion location relative to…
buff.ly
June 22, 2026 at 9:00 AM
Novel insight in #AMD research: a new spatially weighted model captures the true impact of #GeographicAtrophy beyond lesion size. A step toward smarter #Retina imaging. #Ophthalmology #MedTech #VisionScience buff.ly/pes2x9B
A distinct genetic AMD subtype emerges: rare CFH/CFI variants are linked to earlier geographic atrophy and severe drusen burden. #AMD #GeographicAtrophy #Genetics #PrecisionMedicine buff.ly/9Zjotxq
Geographic Atrophy in Patients with Age-Related Macular Degeneration Is Associated with Rare Variants in Complement Factor H and Complement Factor I - PubMed
The authors have no proprietary or commercial interest in any materials discussed in this article.
buff.ly
June 2, 2026 at 9:00 AM
A distinct genetic AMD subtype emerges: rare CFH/CFI variants are linked to earlier geographic atrophy and severe drusen burden. #AMD #GeographicAtrophy #Genetics #PrecisionMedicine buff.ly/9Zjotxq
New study links gut microbiome function, not composition, to complement dysregulation and genetic risk in geographic atrophy, highlighting a systemic gut/immune/retina axis. #GeographicAtrophy #AMD #Microbiome #Genomics #Ophthalmology #Science buff.ly/7yU87jB
Linking the microbiome to the complement system in geographic atrophy - PubMed
Age-related macular degeneration (AMD) is the leading cause of vision loss in the aged population with the late stage geographic atrophy (GA). Risk factors for AMD include age, genetic variants in…
buff.ly
February 3, 2026 at 10:00 AM
New study links gut microbiome function, not composition, to complement dysregulation and genetic risk in geographic atrophy, highlighting a systemic gut/immune/retina axis. #GeographicAtrophy #AMD #Microbiome #Genomics #Ophthalmology #Science buff.ly/7yU87jB
New study shows combining microperimetry with AI-quantified OCT biomarkers captures localized functional loss in geographic atrophy—pointing to more sensitive clinical trial endpoints. #GeographicAtrophy #AMD #Ophthalmology #AIinMedicine #ClinicalTrials buff.ly/DuHs30i
Exploring Trial Endpoints in Geographic Atrophy Based on Localized Functional Changes in Microperimetry and AI-Quantified OCT Biomarkers - PubMed
A significant association between RS in MP and EZ and RPE loss on OCT was established using DL. A reliable quantitative structure/function association provides the base for developing functional…
buff.ly
January 19, 2026 at 9:00 AM
New study shows combining microperimetry with AI-quantified OCT biomarkers captures localized functional loss in geographic atrophy—pointing to more sensitive clinical trial endpoints. #GeographicAtrophy #AMD #Ophthalmology #AIinMedicine #ClinicalTrials buff.ly/DuHs30i
Prelim Phase 2 data hint Ocugen’s AAV5 gene therapy (OCU410) may outperform approved GA treatments at mid-dose, while higher doses raise intriguing biology questions 👀🧬 #GeneTherapy #DryAMD #GeographicAtrophy #Biotech #ClinicalTrials
Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas
Ocugen has reported preliminary phase 2 data on its e | Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform…
buff.ly
January 16, 2026 at 10:00 AM
Prelim Phase 2 data hint Ocugen’s AAV5 gene therapy (OCU410) may outperform approved GA treatments at mid-dose, while higher doses raise intriguing biology questions 👀🧬 #GeneTherapy #DryAMD #GeographicAtrophy #Biotech #ClinicalTrials